Trial Profile
Efficacy and safety of everolimus-eluting stent (Xience Prime) in long coronary lesions
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms LONGPRIME
- 20 Oct 2015 New trial record
- 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.